These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27488420)

  • 1. Comparable Neuroprotective Effects of Pergolide and Pramipexole on Ferrous Sulfate-Induced Dopaminergic Cell Death in Cell Culture.
    Reichelt D; Radad K; Moldzio R; Rausch WD; Reichmann H; Gille G
    CNS Neurol Disord Drug Targets; 2016; 15(10):1325-1332. PubMed ID: 27488420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabergoline protects dopaminergic neurons against rotenone-induced cell death in primary mesencephalic cell culture.
    Meinel J; Radad K; Rausch WD; Reichmann H; Gille G
    Folia Neuropathol; 2015; 53(1):29-40. PubMed ID: 25909873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity.
    Izumi Y; Sawada H; Yamamoto N; Kume T; Katsuki H; Shimohama S; Akaike A
    Eur J Pharmacol; 2007 Feb; 557(2-3):132-40. PubMed ID: 17161393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pergolide protects dopaminergic neurons in primary culture under stress conditions.
    Gille G; Rausch WD; Hung ST; Moldzio R; Janetzky B; Hundemer HP; Kolter T; Reichmann H
    J Neural Transm (Vienna); 2002 May; 109(5-6):633-43. PubMed ID: 12111455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating activated regulatory T cells with pramipexole protects human dopaminergic neurons from 6-OHDA-induced degeneration.
    Guevara-Salinas A; Netzahualcoyotzi C; Álvarez-Luquín DD; Pérez-Figueroa E; Sevilla-Reyes EE; Castellanos-Barba C; Vega-Ángeles VT; Terán-Dávila E; Estudillo E; Velasco I; Adalid-Peralta L
    CNS Neurosci Ther; 2024 Aug; 30(8):e14883. PubMed ID: 39097919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms.
    Gu M; Iravani MM; Cooper JM; King D; Jenner P; Schapira AH
    J Neurochem; 2004 Dec; 91(5):1075-81. PubMed ID: 15569251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity.
    Imamura K; Takeshima T; Nakaso K; Ito S; Nakashima K
    Neurosci Lett; 2008 Aug; 440(2):97-102. PubMed ID: 18555604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from pergolide to pramipexole in patients with Parkinson's disease.
    Hanna PA; Ratkos L; Ondo WG; Jankovic J
    J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole.
    Carvey PM; Pieri S; Ling ZD
    J Neural Transm (Vienna); 1997; 104(2-3):209-28. PubMed ID: 9203083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are dopamine receptor agonists neuroprotective in Parkinson's disease?
    Le WD; Jankovic J
    Drugs Aging; 2001; 18(6):389-96. PubMed ID: 11419913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.
    Costa A; Peppe A; Dell'Agnello G; Caltagirone C; Carlesimo GA
    Neuropsychologia; 2009 Apr; 47(5):1374-81. PubMed ID: 19428401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity.
    Zou L; Jankovic J; Rowe DB; Xie W; Appel SH; Le W
    Life Sci; 1999; 64(15):1275-85. PubMed ID: 10227583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pramipexole protects dopaminergic neurons through paraplegin against 6-hydroxydopamine.
    Kim MK; Park HS; Cho JH; Kim GS; Won C
    Neuroreport; 2015 Jan; 26(2):74-80. PubMed ID: 25514384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramipexole protects against H2O2-induced PC12 cell death.
    Fujita Y; Izawa Y; Ali N; Kanematsu Y; Tsuchiya K; Hamano S; Tamaki T; Yoshizumi M
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Jan; 372(4):257-66. PubMed ID: 16362428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine agonists: the treatment for Parkinson's disease in the XXI century?
    Lledó A
    Parkinsonism Relat Disord; 2000 Nov; 7(1):51-58. PubMed ID: 11008196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine agonist monotherapy in Parkinson's disease.
    Clarke CE; Guttman M
    Lancet; 2002 Nov; 360(9347):1767-9. PubMed ID: 12480442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minocycline protects dopaminergic neurons against long-term rotenone toxicity.
    Radad K; Moldzio R; Rausch WD
    Can J Neurol Sci; 2010 Jan; 37(1):81-5. PubMed ID: 20169778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective effects of pramipexole against tunicamycin-induced cell death in PC12 cells.
    Nakayama H; Zhao J; Ei-Fakhrany A; Isosaki M; Satoh H; Kyotani Y; Yoshizumi M
    Clin Exp Pharmacol Physiol; 2009 Dec; 36(12):1183-5. PubMed ID: 19515063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapamycin protects dopaminergic neurons against rotenone-induced cell death in primary mesencephalic cell culture.
    Radad K; Moldzio R; Rausch WD
    Folia Neuropathol; 2015; 53(3):250-61. PubMed ID: 26443316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.